CorMedix 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- CorMedix reported 3rd quarter 2026 consolidated revenue of $54.5 million, including $17.2 million in DefendCast net sales and $37.3 million from the remainder of the portfolio.
- Adjusted EBITDA was $3.1 million, and the company ended the quarter with $355.2 million in cash and cash equivalents.
- The company recorded a GAAP net loss of $14.7 million, or $0.19 per basic and diluted share, compared with net income of $108.6 million in the 3rd quarter of 2025, which included a $59.7 million tax benefit.
- Total operating expenses were $36.6 million, down from $41.7 million in the 3rd quarter of 2025; R&D expenses were $7 million, selling and marketing expenses were $11.7 million, and G&A expenses were $17.9 million.
- Net cash provided by operating activities for the first 9 months of 2026 was $218.3 million, compared with $80.6 million in the first 9 months of 2025.
- CorMedix announced a definitive agreement to acquire substantially all of Heron Therapeutics' assets, subject to Heron stockholder approval, regulatory clearance, and other customary closing conditions.
- Heron's portfolio generated approximately $150 million of net product revenue over the trailing 12 months, and CorMedix expects the acquired products to contribute approximately $125 to $150 million of revenue for pro forma 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the CorMedix Third Quarter 2026 Earnings and Corporate Update Conference Call. Today's conference call is being recorded. There will be a question-and-answer session at the end of today's presentation, and instructions on how to ask a question will be given at that time. At this time, I would like to turn the conference over to Dan Ferry from LifeSci Advisors.
Please go ahead. Good morning, and welcome to the CorMedix Third Quarter 2026 Earnings and Corporate Update Conference Call.
Leading the call today is Joe Todisco, Chairman and Chief Executive Officer of CorMedix, and he is joined by Susan Blum, EVP and Chief Financial Officer. In addition, Liz Hurlburt, EVP and Chief Operating and Chief Commercial Officer, and Beth Zelnick Kaufman, EVP and Chief Legal and Compliance Officer and Corporate Secretary, will be available during the Q&A session. Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial position.
Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CorMedix filings with the SEC, which are available free of charge at the SEC's website or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in these forward-looking statements, and investors should not place undue reliance on these statements. CorMedix does not intend to update these forward-looking statements, except as required by law. During this call, the company will discuss certain non-GAAP measures of its performance. GAAP to non-GAAP financial reconciliations and supplemental financial information are provided in CorMedix earnings release and the current report on Form 8-K filed with the SEC. This information is also available on the investor relations section of CorMedix's website.
In addition, today's discussion includes statements regarding CorMedix's proposed acquisition of substantially all the assets of Heron Therapeutics, which remains subject to approval by Heron's stockholders, regulatory clearance, and other customary closing conditions. CorMedix has filed a current report on Form 8-K describing the proposed transaction in greater detail. Investors are urged to read it and any other relevant documents CorMedix files with the SEC carefully and in their entirety, because they contain important information about the proposed transaction. At this time, it is now my pleasure to turn the call over to Joe Todisco, Chairman and Chief Executive Officer of CorMedix. Joe, please go ahead. Thanks, Dan.
Good morning, everyone, and thank you for joining us on this call. On Monday, we announced a definitive agreement to acquire substantially all the assets of Heron Therapeutics, encompassing both commercial and pipeline assets that we believe are highly complementary and synergistic with CorMedix's growth strategy in institutional settings of care. As we discussed on Monday, we see four pillars to the strategic rationale for this transaction. First, scale and diversification. The Heron portfolio meaningfully expands our revenue base and further diversifies our revenue mix across acute care and hematology/oncology supportive care, and reduces our reliance on DefenCath revenues to drive cash flow and future growth.
Heron's portfolio generated approximately $150 million of net product revenue over the trailing 12 months, and we expect the acquired products to contribute approximately $125 million-$150 million of revenue for pro forma 2027, roughly doubling the revenue base for our non-DefenCath portfolio. Second, commercial and operational leverage. We expect to deploy Heron's products through our existing infrastructure, supplemented with a subset of the Heron team, which supports the $45 million-$60 million in estimated operating cost synergies that we expect to achieve on an annualized run rate basis by the end of 2027. Third, growth from the acute care franchise. We view ZYNRELEF in particular as an asset with significant untapped potential, as hospitals and surgery centers increasingly adopt non-opioid approaches to post-surgical pain, and together with APONVIE, which serves the same perioperative call point, represents the fastest-growing parts of the Heron portfolio.
Fourth, hematology/oncology supportive care and pipeline optionality. CINVANTI and SUSTOL both bring an established presence in infusion centers and hematology/oncology clinics, which aligns directly with our planned launch of REZZAYO for the prophylaxis indication, if approved by FDA. I also want to highlight how we structure this transaction to align payment with sales performance. Up to $55 million of the consideration is contingent on ZYNRELEF achieving net sales milestones in calendar year 2028, and there are additional contingent payments in the form of a royalty above a sales threshold for CINVANTI, SUSTOL, and any products we launch under the multi-product development agreement. To that extent, a meaningful portion of what we pay is earned only if the assets perform.
We expect the transaction to be immediately accretive to earnings and free cash flow upon closing, which we anticipate in the first quarter of 2027, subject to Heron stockholder approval, regulatory clearance, and other customary closing conditions. Turning to third quarter performance, we continue to execute on our three core strategic priorities. First, executing on our post-TDAPA commercial strategy for DefenCath. Second, meaningfully advancing our high-value pipeline, highlighted by FDA's acceptance of the sNDA for REZZAYO for the prophylaxis of invasive fungal disease with priority review. Third, deploying our capital in a disciplined manner to fuel sustainable growth, highlighted by the Heron announcement. We believe this combination of commercial execution, pipeline progression, and strategic capital allocation positions CorMedix to drive long-term value to shareholders while building an increasingly diversified and resilient business.
For the third quarter, we reported consolidated revenue of $54.5 million, above consensus, and adjusted EBITDA of $3.1 million. We ended the quarter with $355 million in cash. Importantly, our largest dialysis customers largely maintained DefenCath utilization through the quarter at the $2.37 add-on in effect for the second half of 2026. Susan will provide more granular details of third quarter financial results. Turning to guidance. Last week, we reaffirmed our full year 2026 revenue guidance with a range of $325 million-$345 million. Today, we're also narrowing our full year adjusted EBITDA guidance to the top end of the previous range, to $130 million-$140 million.
We also issued a business update last week addressing CMS's release of the ESRD PPS final rule for 2027, as well as comments made by the CFO of a large dialysis organization related to the 2027 post-TDAPA add-on payment for DefenCath. While the ESRD final rule established a post-TDAPA add-on of $8.32 for the first quarter of 2027, which is within our previously guided range, CMS also finalized a new methodology to calculate add-on payments, whereby they will be reset quarterly. Because the quarterly add-on incorporates recent utilization and pricing data, its trajectory quarter to quarter depends on information that only CorMedix can report to CMS. We have not shared that data with any customer or third party, and we believe third-party projections of the quarterly path are subject to significant uncertainty.
As we disclosed in our announcement, this new quarterly mechanism will result in an overall average reimbursement to customers that is lower than the $8.32 over the course of the year. However, based on our review of our own pricing and utilization data, we currently expect the add-on in each quarter of 2027 to exceed the current $2.37, and we currently estimate the full year average to be at least double that current rate. After a decline from Q1 to Q2, we expect the add-on in Q3 and/or Q4 of 2027 to be higher than the second quarter, in each case subject to how CMS applies its methodology, including certain utilization and pricing data in its calculations. Put simply, the lowest add-on we currently expect DefenCath to see in 2027 is higher than our current rate customers receive today.
Our LDO and MDO customers have largely maintained utilization at today's current rate in the third quarter. We are currently engaged in conversations with customers around how to structure DefenCath pricing that tracks the quarterly add-on adjustments, with the goal of keeping fee-for-service patients on therapy throughout the year. We're also actively working to secure separate payment for DefenCath from top Medicare Advantage plans. As a result, we will not be in a position to opine on any 2027 revenue guidance for DefenCath until we have visibility into both customer pricing and expected utilization for Medicare fee-for-service patients, as well as possible upside from Medicare Advantage. In that regard, we are deferring 2027 DefenCath guidance at this time and anticipate being able to update investors in early 2027.
We continue to believe that Medicare Advantage represents a meaningful long-term growth avenue for DefenCath and the best opportunity for the product to have sustainable value following the ending of the post-TDAPA add-on in 2029. DefenCath's clinical value and its potential for meaningful downstream cost savings continue to be supported by a growing body of real-world evidence that our partners are publishing, and I'm proud of the data presentations that took place this past October at the American Society of Nephrology's Kidney Week and at IDWeek. Turning to our pipeline, we announced in October that the sNDA for REZZAYO prophylaxis was accepted for FDA review with priority review status and a target action date from the FDA in the first quarter of 2027.
As a reminder, submission was conducted by our global partner, Mundipharma, following positive clinical trial results from the ReSPECT study, a phase III clinical study evaluating REZZAYO for the prophylaxis of invasive fungal disease in adult immunosuppressed patients undergoing allogeneic bone marrow transplant. We're actively preparing for promotional efforts for REZZAYO in this new indication, and if approved by FDA, would anticipate commencement of promotional efforts in the second half of 2027. Finally, with respect to our phase III TPN study for DefenCath, despite engagement of new study sites and the FDA approval of a protocol amendment that narrows certain exclusion criteria, study enrollment continues to track meaningfully behind our original estimated timelines. Given the established safety profile for DefenCath and demonstrated efficacy in its currently approved indication, we're evaluating potential alternative pathways to pursue approval with FDA should enrollment not accelerate in the next one to two months.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
